0001739074-20-000013.txt : 20201020 0001739074-20-000013.hdr.sgml : 20201020 20201020124440 ACCESSION NUMBER: 0001739074-20-000013 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20201020 DATE AS OF CHANGE: 20201020 EFFECTIVENESS DATE: 20201020 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nuvation Bio Inc. CENTRAL INDEX KEY: 0001829093 IRS NUMBER: 833460372 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-378335 FILM NUMBER: 201247843 BUSINESS ADDRESS: STREET 1: 1500 BROADWAY STREET 2: SUITE 1401 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 650-245-3818 MAIL ADDRESS: STREET 1: 1500 BROADWAY STREET 2: SUITE 1401 CITY: NEW YORK STATE: NY ZIP: 10036 D 1 primary_doc.xml X0708 D LIVE 0001829093 Nuvation Bio Inc. 1500 BROADWAY SUITE 1401 NEW YORK NY NEW YORK 10036 650-245-3818 DELAWARE RePharmation Inc. None Corporation true 2018 David Hung, M.D. 1500 Broadway Suite 1401 New York NY NEW YORK 10036 Executive Officer Director Kim Blickenstaff 1500 Broadway Suite 1401 New York NY NEW YORK 10036 Director Michelle Doig 1500 Broadway Suite 1401 New York NY NEW YORK 10036 Director Robert Bazemore 1500 Broadway Suite 1401 New York NY NEW YORK 10036 Director Claudio Nessi 1500 Broadway Suite 1401 New York NY NEW YORK 10036 Director W. Anthony Vernon 1500 Broadway Suite 1401 New York NY NEW YORK 10036 Director Daniel Welch 1500 Broadway Suite 1401 New York NY NEW YORK 10036 Director Kathryn E. Falberg 1500 Broadway Suite 1401 New York NY NEW YORK 10036 Director Pharmaceuticals Decline to Disclose 06b false 2019-06-17 true true false 0 275348195 275348195 0 Includes $15,000,000 in value of cancelled convertible instruments. false 57 0 0 0 false Nuvation Bio Inc. /s/ David Hung, M.D. David Hung, M.D. Chief Executive Officer 2020-10-20